Spyre Therapeutics
SYRE
SYRE
153 hedge funds and large institutions have $2.65B invested in Spyre Therapeutics in 2025 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 76 increasing their positions, 27 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
114% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 14
12% more funds holding
Funds holding: 137 → 153 (+16)
2.09% less ownership
Funds ownership: 106.45% → 104.36% (-2.1%)
Holders
153
Holding in Top 10
6
Calls
$14.6M
Puts
$2.24M
Top Buyers
| 1 | +$67.4M | |
| 2 | +$48.1M | |
| 3 | +$47.5M | |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$42.4M |
| 5 |
BlackRock
New York
|
+$40.2M |
Top Sellers
| 1 | -$34.2M | |
| 2 | -$24.7M | |
| 3 | -$23.3M | |
| 4 |
Millennium Management
New York
|
-$8.68M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$7.95M |
